Monograph Details
|
|
Endocrine System
> Diabetes
|
|
GLYSET |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
α-glucosidase inhibitor. |
| Generic Name |
|
Miglitol 25mg, 50mg, 100mg; tabs. |
| Indications |
|
Adjunct to diet in type 2 diabetes, alone or with a sulfonylurea. |
| Children |
|
Not recommended. |
| Adults |
|
Take with the first bite of each main meal. Initially 25mg three times daily; may start at 25mg once daily (to minimize GI effects) and gradually increase to 25mg three times daily. Increase to 50mg three times daily after 4–8 weeks; usual max 100mg three times daily. |
| Contraindications |
|
Ketoacidosis. Inflammatory bowel disease. Colonic ulceration. Partial intestinal obstruction or predisposition thereof. Chronic intestinal diseases associated with marked disorders of digestion or absorption. Conditions that may deteriorate from increased intestinal gas formation. |
| Precautions |
|
Significant renal dysfunction (serum creatinine >2mg/dL): not recommended. Use glucose, not sucrose, to treat hypoglycemia. Stress. Monitor 1-hour postprandial blood glucose initially and during titration then glycosylated hemoglobin. Pregnancy (Cat.B): consider using insulin instead. Nursing mothers: not recommended. |
| Interactions |
|
Antagonized by intestinal adsorbents (e.g., charcoal), pancreatin, amylase, other carbohydrate-splitting enzymes. May decrease levels of ranitidine, propranolol. Monitor for hypoglycemia if used with a sulfonylurea. |
| Adverse Reactions |
|
Transient flatulence, diarrhea, abdominal pain. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
